Abstract
Background The efficacy, safety and tolerability of amlodipine (aml) and valsartan (val) single pill combination (SPC) in hypertensive patients was evaluated in the post-marketing, non-interventional study. This sub-analysis aimed to evaluate influence of BMI on efficacy and safety of aml/val SPC. Methods A total of 1184 patients (62.2% female; mean ± SD age: 58 ± 11 years and 26% ≥65 years) under aml/val SPC therapy were included in study at 166 centers in Turkey. Of the patients; 1024 (87%), 862 (73%) and 659 (56%) have attended to the 1st, 2nd and 3rd follow-up visits conducted in median 30 ± 5, 90 ± 11 and 178 ± 17 days after baseline, respectively. Results Mean baseline BMI was 30.0 ± 5.6 kg/m2 and it was <25 kg/m2 in 17% (n = 198, 50% females), 25–29.99 kg/m2 in 37% (n = 436, 53% females) and ≥30 kg/m2 in 45% (n = 538, 74% females) of the patients. The msSBP/DBP (mmHg) decreased to 131.3 ± 0.5/80.5 ± 0.3 at the last visit from 166.5 ± 0.6/98.1 ± 0.4 in the entire group. Similarly, it decreased to 132.1 ± 1.4/79.7 ± 0.7 from 166.6 ± 1.4/96.0 ± 0.9, to 130.6 ± 0.8/79.6 ± 0.5 from 166.6 ± 1.0/98.4 ± 0.6 and to 131.6 ± 0.6/81.4 ± 0.4 from 166.7 ± 0.9/98.6 ± 0.9 in BMI sub-groups, respectively (p < 0.0001 for each). The control ratio (≤140/90 mmHg) was 87% in the entire and all BMI sub-groups. The respond rate at the last visit (DBP<90 mmHg or ≥10 mmHg reduction in DBP compared to baseline) was 95% in entire group whereas 95%, 96% and 94% in BMI sub-groups, respectively. During the study, 150 (13%) patients experienced 174 adverse events (AEs). The most common one was edema and its incidence rose as BMI increased (9%, 11% and 14%, respectively), but the new-onset edema incidence was 5%, 7% and 7% in BMI sub-groups, respectively; since many patients already had edema at the baseline. Conclusions In conclusion, aml/val SPC reduces BP efficaciously independent of BMI while patients with higher BMI seem to be at higher risk for edema.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have